Deoxynucleotidyl transferase terminal interacting protein 1 (DNTTIP1) forms a complex with histone deacetylase (HDAC); however, the relevance of DNTTIP1 in cancer remains unknown. The aim of this study was to examine DNTTIP1 expression and its functional mechanisms in oral squamous cell carcinomas (OSCCs). DNTTIP1 expression was analyzed by quantitative reverse transcriptase-polymerase chain reaction, immunoblotting analysis, and immunohistochemistry. The expression of DNTTIP1 was upregulated significantly in vitro and in vivo, and in patients with OSCC in whom DNTTIP1 was overexpressed and the expression level was correlated significantly (P < 0.05) with tumoral growth. DNTTIP1 knockdown (siDNTTIP1) cells showed depressed cellular proliferation by cell-cycle arrest at the G1 phase with high acetylation of p53 and upregulation of p21
Introduction
Deoxynucleotidyl transferase terminal interacting protein 1 (DNTTIP1) was identified originally as a binding partner of DNA polymerase [1] . The detailed functions of DNTTIP1 have not been clarified yet; however, high expression has been reported in muscles [2] . To date, no reports regarding DNTTIP1 related to cancer research have been published. DNTTIP has two isoforms, DNTTIP1 and DNTTIP2 [3] . The former enhances the DNA polymerase activity and the latter suppresses its activity [4] . Our microarray analysis showed that DNTTIP1 was upregulated in oral squamous cell carcinomas (OSCC) cells compared with human normal oral keratinocytes:HNOKs (cultured from the oral mucosal epithelium of young healthy patients) [5] .
Epigenetic abnormalities are believed to be involved in all stages of cancer progression [6] . Histone acetylation is one of the most investigated pathways for epigenetic regulation [6] . Histone deacetylases (HDACs) are associated closely with the development and progression of cancer and have been reported to cause deacetylation of p53 [7] . p53 deacetylation is assumed to be associated with loss of cancer-suppressing ability, and induction of apoptosis of cancer cells is less likely to occur [8] . HDAC1 forms a complex with DNTTIP1 [9, 10] . Therefore, here, we assumed that DNTTIP1 plays some roles in deacetylation of p53 by HDAC1.
In this study, DNTTIP1 was overexpressed in OSCCderived cell lines and primary OSCCs, and, therefore, we hypothesized that DNTTIP1 might be associated with OSCC. We also clarified the clinical relevance of DNTTIP1 in cancer using a knockdown model and resveratrol, an HDAC inhibitor.
Materials and methods

Ethics statement
The ethical committee of the Graduate School of Medicine, Chiba University, approved the research protocol (protocol number 680). All patients provided written informed consent before inclusion in the study.
Cells and tissue samples
Human OSCC-derived cell lines were purchased from RIKEN BioResource Center (Tsukuba, Ibaraki, Japan) and the Japanese Collection of Research Bioresources Cell Bank (Ibaraki, Osaka, Japan) [11] [12] [13] . We obtained HNOKs from young healthy patients and cultured them as described previously [14] [15] [16] [17] . Three independent HNOKs were primarily cultured and passaged five times in oral keratinocyte medium (ScienCell Research Laboratories, Carlsbad, CA) and 5 ml of penicillin/streptomycin solution (ScienCell Research Laboratories). The HNOKs served as normal control cells.
mRNA expression analysis
Quantitative reverse transcriptase-PCR (qRT-PCR) was carried out as described previously [18] [19] [20] [21] [22] . The sequences of the gene-specific primers and universal probes were as follows: DNTTIP1 (5′-CCTCGATGAGGAGGTAGGC-3′ and 5′-CAGCTGACCCCCAGGATA-3′) and universal probe #20, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (5′-AGCCACATCGCTCAGACAC-3′ and 5′-GCCCAATACGACCAAATCC-3′) and universal probe #60.
Immunoblotting analysis
Protein extraction and immunoblotting analysis were conducted as described previously [23] [24] [25] [26] . Protein concentrations were determined using the Bradford concentration assay (Bradford reagent) and a TECAN Infinite 200 PRO (Tecan Group Ltd., Mannedorf, Switzerland) microplate reader and unified to 20 μg per lane. The antibodies were anti-DNTTIP1 (sc-98407, rabbit), anti-GAPDH (sc-25778, rabbit), anti-cyclin E (sc-377100, mouse) (Santa Cruz Biotechnology; Santa Cruz, CA, USA), anti-CDK2 (#2546, rabbit), anti-CDK4 (#12790, rabbit), anti-CDK6 (#3136, mouse), anti-p21 Cip1 (#2947, rabbit), anti-p27 Kip1 (#3686, rabbit), anti-cyclin D1 (#2978, rabbit), anti-p53 (#2524, rabbit), anti-acetyl-p53 (#2525), and anti-HDAC1 (#34589) (Cell Signaling Technology, Danvers, MA, USA).
Immunohistochemistry (IHC)
IHC was carried out as described previously [27] [28] [29] [30] [31] . The DNTTIP1 IHC score was calculated by combining the proportion and intensity of DNTTIP1 stained cells. The intensities of the stained cells were classified as 0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining.
Transfection with siRNA plasmid
Transfection with siRNA was conducted as described previously [18, 19] . DNTTIP1 siRNA (siDNTTIP1) and control siRNA (siControl) (sc-76640, sc-37007, Santa Cruz Biotechnology) were transfected into HSC2 and HSC4 cells. To investigate the efficiency of DNTTIP1 knockdown, we carried out qRT-PCR and immunoblotting analysis.
Cellular proliferation assay
To examine the effects of DNTTIP1 knockdown and resveratrol treatment on cellular growth, we performed the cellular proliferation assay as described previously [23] [24] [25] [26] .
Cell-cycle analysis
The transfectants were treated with 200 ng/ml nocodazole (Sigma-Aldrich, St. Louis, MO, USA) for 16 h to synchronize cells at the G2/M transition [32, 33] . After treatment, the cells were collected, washed with phosphatebuffered saline, and processed with the CycleTEST Plus DNA reagent kit (Becton-Dickinson, Franklin Lakes, NJ, USA). Flow cytometric determination of the DNA content was analyzed using the BD AccuriTM C6 Flow Cytometer (Becton-Dickinson) [23] [24] [25] [26] .
Resveratrol treatment
Resveratrol (Sigma-Aldrich), a natural phytochemical in fruits, enhances p53 acetylation and suppresses the HDAC1 activity in several types of cancers [31] [32] [33] [34] . To investigate whether resveratrol treatment was related to cellular proliferation and cell cycle, the cells were subjected to treatment with resveratrol (50 µM) for 48 h. We used dimethylsulfoxide (DMSO) as excipients in vitro and in vivo.
In vivo tumor xenograft study
To investigate the cellular proliferation inhibitory effect of resveratrol, we used xenograft models (HSC-2 and HSC-4). The cells (1 × 10 7 cells) were injected independently and subcutaneously. Female nude mice (6-week-old, BALB/cAnu [nu/nu]) were purchased from Oriental Yeast Co. (Tokyo, Japan). The volume of the implanted tumor into the dorsal side of the mice was measured with a digital caliper every 3-4 days after injection. We used the formula 4π/3 × (width/2) 2 × (length/2) to calculate tumoral volume. After the tumors reached approximately 100 mm 3 (~10 days), daily resveratrol intraperitoneal injections (2 mg of resveratrol in 50 μl of DMSO) started for 28 days (three mice/ group), at which time the mice were sacrificed, and tumoral tissues were collected for further analyses.
Statistical analysis
Statistical differences were analyzed by the χ 2 test, Student's t-test, Fisher's exact test, and Mann-Whitney U-test. P < 0.05 indicates statistically significant. All data are expressed as the mean ± standard error (SEM).
Results
Upregulation of DNTTIP1 in OSCC cells
To evaluate the status of DNTTIP1 expression, we conducted qRT-PCR and performed immunoblotting analysis using the nine OSCC cell lines and HNOKs, as normal control cells. DNTTIP1 mRNA expression was upregulated significantly in all nine OSCC cell lines compared with the HNOKs (Fig. 1a , P < 0.05). Figure 1b shows representative results of immunoblotting analysis. The DNTTIP1 protein also increased in all nine OSCC cell lines compared with their counterparts.
Evaluation of DNTTIP1 expression in primary OSCC samples and clinical correlations of clinicopathological features
We evaluated the DNTTIP1 expression in primary OSCCs by IHC. High DNTTIP1 expression was found in the nuclei of the OSCC specimens; the normal oral tissues showed almost negative immunostaining (Fig. 2a) . Representative IHC data for DNTTIP1 in normal tissue and primary OSCC are shown in Fig. 2a . The scores in the normal oral tissues ranged from 2.5 to 75 (median, 33.05) and in primary OSCC tissues ranged from 18.8 to 195.6 (median, 104.5). These IHC scores in primary OSCCs were clearly (P < 0.05) greater than in normal oral tissues (Fig. 2b) . The correlations between the clinicopathological features of patients with OSCC and the state of DNTTP1 protein expression are shown in Table 1 . Of the clinical parameters, the DNTTIP1 expression level was clearly (P < 0.05) related to the primary tumoral size of the OSCCs.
siRNA knockdown of DNTTIP1 from OSCC cells
Since overexpression of DNTTIP1 was seen in OSCC in vitro and in vivo (Figs. 1 and 2) , we transiently transfected siDNTTIP1 and siControl into OSCC cells (HSC-2 and HSC-4). To investigate the efficiency of the transfection, we performed qRT-PCR and immunoblotting analysis. DNTTIP1 mRNA expression in the siDNTTIP1 cells was (Fig. 3a) . DNTTIP1 protein levels in the siDNTTIP1 cells also decreased compared with the siControl cells (Fig. 3b) .
Cellular growth and cell-cycle analysis of siDNTTIP1 cells
To evaluate the effect of DNTTIP1 knockdown on cellular growth, a cellular proliferation assay was performed. We found a significant (P < 0.05) decrease in cellular proliferation in the siDNTTIP1 cells compared with the siControl cells (Fig. 4a) . We also assessed the cell-cycle distribution by flow cytometry (Fig. 4b) , since the cellular growth of the DNTTIP1 knockdown cells decreased compared with the control. The percentage of the siDNTTIP1 cells at the G1 phase was clearly (P < 0.05) higher than that of the siControl cells (Fig. 4b) . Assessment of the expression levels of the cyclin-dependent kinase inhibitors (CDKIs) (p21 Cip1 and p27 Kip1 ), CDKs (CDK2, CDK4, and CDK6), and cyclins (cyclin D1 and cyclin E) showed that the CDKIs were upregulated, and CDKs and cyclins were downregulated in the siDNTTIP1 cells (Fig. 4c) . These results indicated that siDNTTIP1 inhibited cellular proliferation by cell-cycle arrest at the G1 phase.
Resveratrol treatment
To investigate the effect of resveratrol, we first performed the cellular proliferation assay. The cellular growth of the resveratrol-treated cells was significantly (P < 0.05) lower than that of control cells (HSC-2 and HSC-4) (Fig. 5a ). In the cell-cycle analysis, the percentage of the resveratroltreated cells at the G1 phase was clearly (P < 0.05) higher than that of control cells (Fig. 5b) . Assessment of the expression levels of DNTTIP1, CDKIs, CDKs, and cyclins using immunoblotting analysis after treatment with resveratrol showed that the DNTTIP1, CDKs, and cyclin levels were downregulated, and the CDKI levels were upregulated in the resveratrol-treated cells compared with the control cells (Fig. 5c) .
p53, acetyl-p53, and HDAC1 expression levels in DNTTIP1 knockdown cells and resveratrol-treated cells
To investigate the effect of DNTTIP1 knockdown and resveratrol treatment, we assessed p53, acetyl-p53, and HDAC1 expression levels using immunoblotting analysis. The acetyl-p53 levels were upregulated in the siDNTTIP1 and resveratrol-treated cells. The p53 and HDAC1 levels did not change after siRNA and resveratrol treatments (Fig. 6 ).
Resveratrol inhibited tumoral growth in vivo
We appraised the effect of resveratrol on tumoral growth in vivo using target tumor xenografts in nude mice. OSCC cells (HSC-2 and HSC-4) were injected subcutaneously into the backs of female nude mice (three mice in each group). The tumoral volume of the resveratrol-treated group was clearly (P < 0.05) smaller than that of the control group (Fig. 7a) . After resveratrol treatment, the xenografted tumors showed a significant decrease in DNTTIP1 expression (Fig. 7b) . Resveratrol did not affect the body weight of the mice compared with the control group (data not shown).
Discussion
In the current study, overexpressed DNTTIP1 was observed in OSCC in vitro and in vivo and was correlated positively with tumoral growth. The siDNTTIP1 cells showed decreased cellular proliferation through cell-cycle arrest at the G1 phase. Interestingly, resveratrol, the HDAC inhibitor, controlled DNTTIP1 expression and led to a similar phenotype of DNTTIP1 knockdown cells [35] [36] [37] . A recent study reported that DNTTIP1 binds to HDAC1 and forms a complex [9, 10, 38] . Although the detailed functions of DNTTIP1 in cancer remain unknown, HDAC1, the binding partner of DNTTIP1, is associated closely with the development and progression of cancers [7] . HDACs cause deacetylation of p53 [8] , leading to loss of the tumoral suppressing function of p53. Acetylated p53 upregulates p21
Cip1 to direct cell-cycle arrest at the G1 phase [39] [40] [41] . Similar to previous data, our DNTTIP1 knockdown cells also showed cell-cycle arrest at the G1 phase with upregulation of p21
Cip1 and p27 Kip1 and downregulation of cyclin D1 and cyclin E. Members of the Cip/Kip family are implicated in negative regulation of cell-cycle progression from the G1 to S phase by binding and modulating CDK [39] [40] [41] . Resveratrol modulates multiple cellular signaling pathways, such as the antioxidant, anti-inflammatory, and inhibitory activities of tumoral growth [42] [43] [44] [45] [46] [47] [48] [49] . In silico docking analysis showed that resveratrol has the highest binding capacity of all the 11 human HDAC enzymes [50, 51] . Resveratrol promotes acetylation of p53 and thus increases the expression of p53-target genes that participate in cell-cycle arrest [52, 53] .
Since siDNTTIP1 inhibited HDAC1 activity leading to increased acetylated p53, we investigated whether resveratrol regulated not only HDAC activity but also DNTTIP1 expression. In addition to the in vitro experiments using resveratrol, xenografted tumors after intraperitoneal injection with resveratrol were characterized by inhibited tumoral growth and negative staining for DNTTIP1 by IHC (Fig. 7b) , indicating that DNTTIP1 silencing and resveratrol treatment have similar effects on cancer progression. Although resveratrol is compatible with the binding pocket of several HDACs as the inhibitor, DNTTIP1 interacts with the specific target, HDAC1. Therefore, the non-targeting effects of DNTTIP1 are substantially lower than those of resveratrol.
In conclusion, this study is the first to reveal that DNTTIP1 plays a crucial role in cancer progression in OSCC by controlling the status of p53 acetylation through DNTTIP1-HDAC1 interaction. Thus, our data suggested that DNTTIP1 might be a potential biomarker for cancer growth and a novel therapeutic target in OSCCs. 
